What role does the Talasaz and Eskandari 2017 Family Trust play in GH share ownership?

The trust holds Guardant Health common stock indirectly for the reporting person. After March 13, 2026 transactions, including RSU conversions and tax withholding, it held 2,128,489 shares, following a transfer of 13,209 shares from direct to indirect ownership as noted in the footnotes.

How do the January 1, 2026 RSU vesting events affect GH share counts for the insider?

On January 1, 2026, 38,283 restricted stock units converted into common shares, with 19,402 shares withheld for taxes. A related restructuring moved 13,209 shares from direct ownership into the family trust, consolidating holdings while keeping the economic exposure within the same affiliated group.

Guardant Health (GH) Co-CEO logs RSU grants, tax withholding and trust share transfer

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Guardant Health Co-CEO AmirAli Talasaz reported compensation-related equity activity and trust-related share movements. On March 17, 2026, he received awards of 11,268 and 101,409 restricted stock units that vest over quarterly and multi-year schedules. Earlier, on January 1 and March 13, 2026, performance-based and time-based RSUs covering 38,283 and 26,961 shares were exercised into common stock, with 19,402 and 13,664 shares withheld by the company to cover tax obligations. In connection with these events, 13,209 common shares were transferred from direct ownership into the Talasaz and Eskandari 2017 Family Trust, which held 2,128,489 shares after the March 13, 2026 transactions.

Insider Trade Summary

65,244 shares exercised/converted

Mixed 10 txns

Insider Talasaz AmirAli

Role Co-Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	11,268	$0.00	--
Grant/Award	Restricted Stock Units	101,409	$0.00	--
Exercise	Performance-Based Restricted Stock Units	26,961	$0.00	--
Exercise	Common Stock	26,961	$0.00	--
Tax Withholding	Common Stock	13,664	$85.49	$1.17M
Exercise	Restricted Stock Units	38,283	$0.00	--
Other	Common Stock	13,209	$0.00	--
Other	Common Stock	13,209	$0.00	--
Exercise	Common Stock	38,283	$0.00	--
Tax Withholding	Common Stock	19,402	$102.14	$1.98M

Holdings After Transaction: Restricted Stock Units — 11,268 shares (Direct); Performance-Based Restricted Stock Units — 0 shares (Direct); Common Stock — 2,142,153 shares (Indirect, Shares held by Talasaz and Eskandari 2017 Family Trust); Common Stock — 0 shares (Direct)

Footnotes (1)

Reflects changes in form of ownership from direct to indirect due to transfer of shares to Talasaz and Eskandari 2017 Family Trust. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. This represents a restricted stock unit award granted on March 12, 2025 that vested with respect to 33% of the shares on January 1, 2026 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. Not applicable for Restricted Stock Units. This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. This represents a restricted stock unit award granted on March 17, 2026 that vests over a three-year period. 33% of the shares subject to such award vests on January 1, 2027 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/17/2026 - 09:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Talasaz AmirAli

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/01/2026		J		13,209⁽¹⁾	D	$0	0	D
Common Stock	01/01/2026		J		13,209⁽¹⁾	A	$0	2,096,311	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	01/01/2026		M		38,283	A	$0	2,134,594	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	01/01/2026		F		19,402⁽²⁾	D	$102.14	2,115,192	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	03/13/2026		M		26,961	A	$0	2,142,153	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	03/13/2026		F		13,664⁽²⁾	D	$85.49	2,128,489	I	Shares held by Talasaz and Eskandari 2017 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	01/01/2026		M			38,283	⁽³⁾	⁽⁴⁾	Common Stock	38,283	$0	77,727	D
Performance-Based Restricted Stock Units	$0	03/13/2026		M			26,961	03/13/2026	⁽⁴⁾	Common Stock	26,961	$0	0	D
Restricted Stock Units	$0	03/17/2026		A		11,268		⁽⁵⁾	⁽⁴⁾	Common Stock	11,268	$0	11,268	D
Restricted Stock Units	$0	03/17/2026		A		101,409		⁽⁶⁾	⁽⁴⁾	Common Stock	101,409	$0	101,409	D

Explanation of Responses:

1. Reflects changes in form of ownership from direct to indirect due to transfer of shares to Talasaz and Eskandari 2017 Family Trust.

2. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

3. This represents a restricted stock unit award granted on March 12, 2025 that vested with respect to 33% of the shares on January 1, 2026 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter.

4. Not applicable for Restricted Stock Units.

5. This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.

6. This represents a restricted stock unit award granted on March 17, 2026 that vests over a three-year period. 33% of the shares subject to such award vests on January 1, 2027 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Guardant Health (GH) Co-CEO AmirAli Talasaz report in this Form 4?

He reported new restricted stock unit grants, vesting-related exercises, tax-withholding share dispositions, and a transfer of common shares into a family trust, reflecting compensation and ownership-structure updates rather than open-market buying or selling activity.

How many new restricted stock units did GH grant to AmirAli Talasaz?

He received two new restricted stock unit awards on March 17, 2026, covering 11,268 and 101,409 underlying shares of Guardant Health common stock, with vesting spread across quarterly dates and a three-year period, subject to continued service and applicable award terms.

Were any Guardant Health (GH) shares sold on the open market in this filing?

No open-market sales were reported. Shares labeled with transaction code F, totaling 19,402 and 13,664 shares, were retained by the company solely to satisfy tax withholding obligations tied to vesting, rather than discretionary market sales by the insider.

What performance-based equity activity did AmirAli Talasaz report for Guardant Health (GH)?

He exercised 26,961 performance-based restricted stock units on March 13, 2026, converting them into an equal number of Guardant Health common shares held through the family trust, demonstrating settlement of previously granted performance-linked awards rather than new market purchases.